{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:45:56Z","timestamp":1761677156070,"version":"build-2065373602"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.critrevonc.2023.103917","type":"journal-article","created":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T09:37:47Z","timestamp":1674380267000},"page":"103917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Advancements and future trends of immunotherapy in light-chain amyloidosis"],"prefix":"10.1016","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-5510","authenticated-orcid":false,"given":"Himil","family":"Mahadevia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Ponvilawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parth","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Al-Obaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagadish","family":"Koyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2023.103917_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.103917_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive Review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2023.103917_bib3","unstructured":"Barbara Ann Karmanos , 2017. Cancer I, National Cancer I, Bristol-Myers S, Multiple Myeloma Research C. Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis.."},{"issue":"10214","key":"10.1016\/j.critrevonc.2023.103917_bib4","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103917_bib5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/hematology.2021000305","article-title":"AL amyloidosis: untangling new therapies","volume":"2021","author":"Bal","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103917_bib6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103917_bib7","unstructured":"Caelum Biosciences I, Pharmaceuticals A, Published 2021. A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis. https:\/\/ClinicalTrials.gov\/show\/NCT04504825. Updated February 2. Accessed."},{"key":"10.1016\/j.critrevonc.2023.103917_bib8","unstructured":"Caelum Biosciences I, Pharmaceuticals A, Published 2020. A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis. https:\/\/ClinicalTrials.gov\/show\/NCT04512235. Updated November 12. Accessed."},{"key":"10.1016\/j.critrevonc.2023.103917_bib9","unstructured":"Cellectis S.A. , 2019. Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed\/Refractory Multiple Myeloma (MELANI-01)."},{"key":"10.1016\/j.critrevonc.2023.103917_bib10","unstructured":"Center for Drug Evaluation and Research, Published 2021. FDA Grants Accelerated Approval to Darzalex Faspro for Newly Diagnosed Light Chain Amyloidosis. FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-darzalex-faspro-newly-diagnosed-light-chain-amyloidosis (Accessed 8 August 2022)."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103917_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/leu.2017.302","article-title":"A compound chimeric antigen receptor strategy for targeting multiple myeloma","volume":"32","author":"Chen","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2023.103917_bib12","unstructured":"City of Hope Medical C, National Cancer I, 2019. CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma."},{"key":"10.1016\/j.critrevonc.2023.103917_bib13","unstructured":"Matteo I.P.S. Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis, 2021."},{"issue":"18","key":"10.1016\/j.critrevonc.2023.103917_bib14","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2023.103917_bib15","article-title":"Incidence and prevalence of light chain amyloidosis: a population-based study","volume":"130","author":"Duhamel","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103917_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","article-title":"Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen","volume":"27","author":"Dumas","year":"2020","journal-title":"Amyloid"},{"issue":"25","key":"10.1016\/j.critrevonc.2023.103917_bib17","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103917_bib18","unstructured":"Emory U., 2024. Sanofi, National Cancer I. Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis."},{"issue":"25","key":"10.1016\/j.critrevonc.2023.103917_bib19","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","article-title":"Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives","volume":"74","author":"Ganatra","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.critrevonc.2023.103917_bib20","doi-asserted-by":"crossref","unstructured":"Gao Y.-J., Shen K., Chang L., et al. Efficacy and Safety of Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Patients with Mayo 2004 Stage 3 Light-Chain Amyloidosis: A Prospective Phase 2 Study. Paper presented at: ASH Annual Meeting 2022; New Orleans, Louisana, USA.","DOI":"10.1182\/blood-2022-157044"},{"key":"10.1016\/j.critrevonc.2023.103917_bib21","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S2152-2650(21)02156-X","article-title":"P-022: Survival benefit observed with Birtamimab in Mayo Stage IV AL amyloidosis supports initiation of confirmatory AFFIRM-AL phase 3 study","volume":"21","author":"Gertz","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2023.103917_bib22","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2019-124482","article-title":"Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients","volume":"134","author":"Gertz","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103917_bib23","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.103917_bib24","unstructured":"Intergroupe Francophone du M, Sanofi, Bristol-Myers S., 2024. Isatuximab Plus Pomalidomide and Dexamethasone, Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103917_bib25","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.clml.2018.08.021","article-title":"Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma","volume":"19","author":"Iqbal","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2023.103917_bib26","article-title":"Development LLC","author":"Janssen","year":"2024","journal-title":"A Study Daratumumab-Based Ther. Particip. Amyloid Light Chain (AL) Amyloidosis."},{"key":"10.1016\/j.critrevonc.2023.103917_bib27","doi-asserted-by":"crossref","unstructured":"Kastritis E., Palladini G., Dimopoulos M.-A., et al. 2022b. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. Paper presented at: ASH Annual Meeting 2022b; New Orleans, Louisiana, USA.","DOI":"10.1097\/01.HS9.0000967704.23014.16"},{"key":"10.1016\/j.critrevonc.2023.103917_bib28","doi-asserted-by":"crossref","unstructured":"Kastritis E., Minnema M.C., Dimopoulos M.-A., et al., 2022a. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. Paper presented at: ASH Annual Meeting2022a; New Orleans, Louisiana, USA.","DOI":"10.1097\/01.HS9.0000846528.55550.9c"},{"issue":"20","key":"10.1016\/j.critrevonc.2023.103917_bib29","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","article-title":"Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103917_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2023.103917_bib31","article-title":"Daratumumab monotherapy in thirty-two heavily pre-treated patients with advanced systemic light-chain amyloidosis","volume":"130","author":"Kimmich","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103917_bib32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103917_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in olmsted county, Minnesota, 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.critrevonc.2023.103917_bib34","doi-asserted-by":"crossref","unstructured":"Lee H.C., Kaufman G.P., Feng L., et al., 2022. Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis. Paper presented at: 64th ASH Annual Meeting and Exposition; New Orleans, Louisiana, USA.","DOI":"10.1182\/blood-2022-167555"},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2023.103917_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8006","article-title":"Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed\/refractory (R\/R) multiple myeloma (MM)","volume":"40","author":"Lesokhin","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103917_bib36","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1177\/0300060518814337","article-title":"Multiorgan involvement by amyloid light chain amyloidosis","volume":"47","author":"Li","year":"2019","journal-title":"J. Int. Med. Res."},{"issue":"13","key":"10.1016\/j.critrevonc.2023.103917_bib37","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0735-1097(16)31302-X","article-title":"NEOD001 demonstrates cardiac and renal biomarker responses in a phase 1\/2 study in patients with amyloid light chain amyloidosis and persistent organ dysfunction","volume":"67","author":"Liedtke","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103917_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.103917_bib39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103917_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.103917_bib41","unstructured":"Ltd. PB , Published 2016. The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis. https:\/\/ClinicalTrials.gov\/show\/NCT02632786. Updated March. Accessed."},{"key":"10.1016\/j.critrevonc.2023.103917_bib42","unstructured":"Ltd. PB,Published 2021. A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis. https:\/\/ClinicalTrials.gov\/show\/NCT04973137. Updated August 30. Accessed."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.103917_bib43","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab Mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103917_bib44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/13506120309041732","article-title":"Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis","volume":"10","author":"Matsuda","year":"2003","journal-title":"Amyloid"},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2023.103917_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8015","article-title":"Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1.","volume":"40","author":"Minnema","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10292","key":"10.1016\/j.critrevonc.2023.103917_bib46","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103917_bib47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103917_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.103917_bib49","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.critrevonc.2023.103917_bib50","unstructured":"National Comprehensive Cancer Network. Systemic Light Chain Amyloidosis (Version 1.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/amyloidosis.pdf. Published 2022. (Accessed 16 July 2022)."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103917_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003783","article-title":"First report of CART treatment in AL amyloidosis and relapsed\/refractory multiple myeloma","volume":"9","author":"Oliver-Caldes","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103917_bib52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103917_bib53","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.103917_bib54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2023.103917_bib55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-143180","article-title":"A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)","volume":"136","author":"Parker","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.103917_bib56","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103917_bib57","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","article-title":"2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis (\u2020)","volume":"23","author":"Renz","year":"2016","journal-title":"Amyloid"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.103917_bib58","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.103917_bib59","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2023.103917_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ijms21114129","article-title":"CD38 and Anti-CD38 monoclonal antibodies in AL amyloidosis: targeting plasma cells and beyond","volume":"21","author":"Roccatello","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.103917_bib61","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcyt.2017.03.077","article-title":"Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis","volume":"19","author":"Rosenzweig","year":"2017","journal-title":"Cytotherapy"},{"issue":"18","key":"10.1016\/j.critrevonc.2023.103917_bib62","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2023.103917_bib63","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103917_bib64","unstructured":"Sandy Wong M.D., Janssen P., 2026. AbbVie, University of California SF. Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)."},{"key":"10.1016\/j.critrevonc.2023.103917_bib65","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3389\/fimmu.2018.01676","article-title":"CD38 as immunotherapeutic target in light chain amyloidosis and multiple myeloma-association with molecular entities, risk, survival, and mechanisms of upfront resistance","volume":"9","author":"Seckinger","year":"2018","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.103917_bib66","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2016-06-722496","article-title":"First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis","volume":"128","author":"Sher","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103917_bib67","unstructured":"Sorrento Therapeutics I. , 2021. Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.103917_bib68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2023.103917_bib69","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2023.103917_bib70","unstructured":"Tufts Medical C, Sanofi, 2024. Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis."},{"key":"10.1016\/j.critrevonc.2023.103917_bib71","unstructured":"University of Texas Southwestern Medical C, GlaxoSmithKline, 2026. Phase 1\/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis."},{"key":"10.1016\/j.critrevonc.2023.103917_bib72","doi-asserted-by":"crossref","unstructured":"Valent J., Silowsky J., Kurman M.R., et al., 2021. Updated organ response results of an open-label study to evaluate the safety and tolerability of CAEL-101 in patients with AL amyloidosis receiving anti-plasma cell therapy. Blood. 138(SUPPL 1):2724.","DOI":"10.1182\/blood-2021-148905"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103917_bib73","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0735-1097(22)01296-7","article-title":"Safety and tolerability of CAEL-101, an anti-amyloid monoclonal antibody, in combination with plasma cell dyscrasia therapy in patients with light-chain amyloidosis: results from a phase 2 study","volume":"79","author":"Valent","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.103917_bib74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol. Rev."},{"issue":"19","key":"10.1016\/j.critrevonc.2023.103917_bib75","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103917_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-021-02407-6","article-title":"Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study","volume":"22","author":"Wechalekar","year":"2022","journal-title":"BMC Cardiovasc. Disord."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.103917_bib77","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.103917_bib78","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2023.103917_bib79","unstructured":"Weill Medical College of Cornell U, Janssen Scientific Affairs LLC, 2020. Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed\/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.103917_bib80","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00277-022-04890-z","article-title":"Belantamab mafodotin in patients with relapsed\/refractory AL amyloidosis with myeloma","volume":"101","author":"Zhang","year":"2022","journal-title":"Ann. Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:45:52Z","timestamp":1760903152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823000057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":80,"alternative-id":["S1040842823000057"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103917","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements and future trends of immunotherapy in light-chain amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103917"}}